A Correlative Study of Fine Needle Aspiration Cytology with Histopathology of Female Breast Lesions

Phirthangmoi Fimate¹

¹Department of Pathology, Jawaharlal Nehru Institute of Medical Sciences (JNIMS), Imphal, Manipur, India.

ABSTRACT

BACKGROUND

Breast lesions remain a major public health problem worldwide. Fine needle aspiration cytology (FNAC) has become one of the first-line investigations for the diagnosis of breast lumps. Although one of the major goals of FNAC is to differentiate benign from malignant lesions, in certain cases, this may not possible due to a lack of uniformity with regards to the reporting terminology used in breast cytology by pathologists worldwide, resulting in poor communication of results among health-care providers. The present study aims to evaluate the role and diagnostic accuracy of FNAC in the evaluation of breast lesions using the National Cancer Institute (NCI) recommended terminology by correlating with histopathological examination (HPE) results.

METHODS

In this retrospective study conducted over a period of two years, a total of 382 female patients with breast lesions underwent FNAC and was categorized according to the NCI guidelines. Of these, 156 cases had histopathological follow-up and their FNAC diagnoses were compared. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) along with 95% confidence interval (95% CI) and accuracy of FNAC were calculated.

RESULTS

Among the 156 cases, none were unsatisfactory (C1); 105 (67.1%) were benign (C2); 7 (4.4%) were atypical but probably benign (C3); 2 (1.1%) were suspicious favouring malignancy (C4); 43 (27.4%) were malignant (C5). Cyto-histopathological correlation was carried out. Of categories C2 and C3 (total of 112 cases), 109 were confirmed as benign (true negative) and the remaining 3 cases turned out to be malignant (false negative). Of categories C4 and C5 (total of 45 cases), all cases were confirmed as malignant (true positive) and none were benign (false positive). The present study showed a sensitivity, specificity, PPV, NPV and accuracy of 93.62% (95% CI, 82.46%–98.66%), 100% (95% CI, 96.67%–100%), 100% (95% CI, 92.5%–99.6%), 97.32% (95% CI, 92.4%–99.09%) and 98.08% respectively.

CONCLUSIONS

Our study concluded that FNAC is a rapid and effective method, and reporting of smears using NCI guidelines highly correlated with the histopathological diagnosis.

KEY WORDS

Breast Lesions, Cytodiagnosis, Histopathologic Diagnosis, Fine-Needle Aspiration Cytology, Histopathological Examination, National Cancer Institute Corresponding Author: Dr. Phirthangmoi Fimate, Ebenezer Villa, Near Shija Hospital, Langol, Imphal West-795004, Manipur, India. E-mail: drmoite@gmail.com

DOI: 10.14260/jemds/2020/246

Financial or Other Competing Interests: None.

How to Cite This Article: Fimate P. A correlative study of fine needle aspiration cytology with histopathology of female breast lesions. J. Evolution Med. Dent. Sci. 2020;9(14):1135-1139, DOI: 10.14260/jemds/2020/246

Submission 30-01-2020, Peer Review 15-03-2020, Acceptance 21-03-2020, Published 06-04-2020.



BACKGROUND

Lesions of the breast constitute a major public health problem worldwide, both in developed as well as in developing countries.¹⁻³ A palpable breast lump, whether benign or malignant, is a cause of great anxiety to the patient.⁴ Thus, the need arises to distinguish benign from malignant lesions, prior to definitive treatment. Fine needle aspiration cytology (FNAC) is a simple procedure that involves passing a fine (22-24 G) needle fitted to an air-tight syringe, through the skin, to sample fluid or tissue from a solid or cystic mass. The extracted material is skilfully smeared onto a glass slide and is air- dried or fixed, stained rapidly, studied and diagnosis rendered promptly.⁵

Investigations like ultrasonography and mammography are used as an adjunct to FNAC, with biopsy as the standard procedure in the diagnosis of breast lesions. The triple test approach, which comprises clinical breast examination, radiological imaging (sonography and mammography), and pathological assessment with FNAC however remains an excellent tool in the initial assessment of palpable breast lumps as well as for screening asymptomatic patients.^{1,6,7} But each of these techniques have their own advantages and limitations.^{6,8,9}

Histopathologic studies still remain the gold standard or reference point for establishing the diagnostic accuracy of cytological smears. However, surgical biopsy (either core needle biopsy [CNB] or excision) results in a large burden of surgery with major preparations, high cost (as compared to FNAC), hospital reservations, medico-legal complications, technological complexities and a large staff, long tissue processing time, cumbersome, and time consuming results, complications, interpretations,^{1,9} patient discomfort such as pain, infection, bleeding and haematoma, and the risk of seeding of the tumour along the needle track in case of core biopsies.⁶ Hence, FNAC helps to determine when the surgical approach is warranted.

With the obvious advantages of ease, simplicity, rapidity, inexpensive and virtually painless procedure and with a high percentage of sensitivity, specificity, accuracy and virtually no complications, FNAC has become a standard tool and one of the first-line investigations for the diagnosis of breast lumps.^{1-6,8,10,11} Moreover, FNAC is a relatively safe procedure in certain circumstances like very small lesions, superficial lesions, or lesions very close to the chest wall as compared to biopsies. In addition, FNAC maintains tactile sensitivity, allows multi-directional passes allowing a broader sampling of lesion, and immediate reporting whenever necessary.¹

FNAC is not only useful in diagnosis and further planning of treatment without need for biopsy, but also helpful in prognostication of the tumour factors such as nuclear grading, mitotic index, hormone receptor status and DNA contents.² Especially in developing countries and countries with limited resources, majority of breast malignancies are advanced⁷ and an unequivocal pre-operative diagnosis of malignancy is frequently required by surgeons in order to justify a more intense medical evaluation for metastatic disease. In such settings, FNAC serves as a cost-effective alternative to open surgical biopsy. However, successful FNAC demands high specimen quality and experience on part of both the aspirator and the cytopathologist.⁹

Accurate pathological diagnosis is crucial for further treatment and estimation of an outcome. One of the major goals of FNAC is to differentiate benign from malignant lesions. However, in certain instances, differentiation of benign from malignant lesion is not possible due to significant overlap on smears and also when there is a paucity of cells. To address these cytomorphologic uncertainties and to bring a higher degree of uniformity to the reporting terminology so as to limit false positive or false negative results, the National Cancer Institute (NCI) proposed five diagnostic categories, based on the National Health Services Breast Screening Programme (NHSBSP) of Britain proposed in 1996 namely, C1, C2, C3, C4 and C5.^{1,4}

In the present study, we aim to evaluate the role and diagnostic accuracy of FNAC in the evaluation of breast lesions using the NCI recommended terminology by correlating with histopathological results.

METHODS

Ethical clearance was applied for and obtained from the Institutional Ethics Committee before the commencement of the present study. A retrospective study was conducted over a period of two years, i.e., between the period of January 2011 to December 2012. The data of all patients presenting with breast lump who underwent FNAC in the Cytology division of Pathology Department, JNIMS, Manipur, during this period were retrieved and reviewed. Only the female breast cases were further analysed. Details concerning age, laterality and site of the breast lesions were recorded. Available cytopathologic reports and slides were retrieved and the cytomorphological features of all the lesions were further studied.

Informed consent had been taken. All patients had been made to lie down on the examination bed and all breast lump aspirates had been performed using 22-24-gauge needle and 10 mL syringe by the cytopathologist under aseptic precautions. The aspirated material was then smeared onto a minimum of 5 clean, dry and grease-free slides. One slide was rapidly stained with Leishman stain for a minute and examined for sample adequacy. Three slides were air dried and stained with May-Grunwald-Giemsa stain. One slide was wet-fixed in 95% ethyl alcohol and subsequently stained with Papanicolaou stain. The stained smears were then classified into five major diagnostic categories after screening and interpretation by applying the probabilistic approach⁴: These were C1, Non diagnostic/unsatisfactory/unremarkable; C2, Benign; C3, Atypical; C4, Suspicious for malignancy; and C5, Malignant.

Records of subsequent excisional biopsies or mastectomies were also retrieved from the Histopathology division of Pathology Department. Specimens had been fixed in 10% formalin solution, routinely processed, sectioned and stained with haematoxylin and eosin staining methods for microscopic examination. The histopathologic examination (HPE) reports and slides were retrieved and reviewed. Comparison was made with the corresponding cytopathology

Jemds.com

reports and codes for correlation. Patients with C2 and C3 diagnoses by FNAC and confirmed as benign on HPE were taken as true negative, while those confirmed as malignant on HPE were considered as false negative. Patients with C4 and C5 diagnoses by FNAC but confirmed as benign on HPE were considered as false positive, while those confirmed as malignant were considered true positive.

Statistical Analysis

All the statistical analysis was performed using Statistical Package for Social Sciences Statistics (SPSS) version 20. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) along with 95% confidence interval (95% CI), accuracy, false positive rate, and false negative rate of FNAC for diagnosing malignant breast lesions were calculated. Qualitative data are summarized using frequency and percentage.

RESULTS

There was a total of 382 cases of female breast FNAC's during the period of January 2011 to December 2012. Satisfactory aspirates were obtained in all of the cases. The age at presentation ranged from 14 to 75 years with a mean age of 34 years with SD of 11.8 years. Benign lesions were more common in 21–30 years and malignant lesions in 41–50 years (Table 1). All of the female patients presented with a unilateral breast lump. The right breast (213, 55.8%) and the upper outer quadrant (263, 68.8%) were most commonly involved. (Table 2). Among the 382 female breast FNAC cases, there were no category C1 cases (all satisfactory smears), C2 consisted of 290 (75.8%), C3 consisted of 22 (5.8%), C4 consisted of 4 (1%), and C5 consisted of 66 (17.3%) cases. Out of 290 cases of category C2, fibroadenoma (42.1%, 161/382) was most common lesion as shown in Table 1.

Of these 382 FNAC cases, histopathological examination (HPE) report was documented in 156 cases with a biopsy rate of 40.8% of which, none were C1, 105 (67.1%) were C2, 7 (4.4%) were C3, 2 (1.1%) were C4, and 43 (27.4%) were C5 as in Table 3. The comparison of these 156 cases of FNAC diagnoses with corresponding HPE diagnoses was done. On HPE, 99% (104/105) cases of C2 were confirmed as benign and the remaining 1 case turned out to be malignant (infiltrating lobular carcinoma, ILC). In C3, benign lesions were confirmed in 71.4% (5/7) and the remaining two cases (28.6%) were diagnosed to be malignant. In both C4 and C5, all the cases were correctly cytodiagnosed as malignant with a cyto-histological concordance of 100% (45/45). The most common malignant lesion noted in C5 on HPE was invasive ductal carcinoma-not otherwise specified (IDC-NOS, 43/47, 91.5%). (Table 3)

The present study showed a sensitivity of 93.62% (95% CI, 82.46%-98.66%), specificity of 100% (95% CI, 96.67%-100%), PPV of 100% (95% CI, 92.5%-99.6%), NPV of 97.32% (95% CI, 92.4%-99.09%), and accuracy of 98.08% for FNAC in the diagnosis of malignant lesions. The false positive and false negative rate was 0% and 6.4%, respectively.

Original Research Article

31-40 29 17 8 14 1 0 0 12 2 20 103 27.0 51-60 2 0 1 1 22 7 8 6 30 0 0 0 1 1 12 27 18.0 61-70 0	Age a $\frac{9}{24}$ $\frac{1}{2}$ 22 <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				C2			C3 C4	C5			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age	A	sis	i A	al.	cta. nulo	pical	дunt	'otal %		
21-30 73 20 7 14 1 3 1 5 0 2 126 33 32 41-50 11 8 5 21 0 0 0 12 2 00 32 72 18 34 51-60 2 0 1 2 0 0 0 1 1 12 22 14 14 10 51-60 2 0 1 0 0 0 0 0 0 0 0 1 1 10 13 10 15 10 11 10 13 10 10 13 10 <th< td=""><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>ŀ</td><td><u> </u></td><td>FA</td><td>E E</td><td>G</td><td>La. Grai</td><td>Aty] Suspi</td><td>Mali</td><td></td></th<>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ŀ	<u> </u>	FA	E E	G	La. Grai	Aty] Suspi	Mali			
31-40 29 17 8 14 1 0 0 12 2 20 10.3 27.0 18.8 51-60 2 0 1 2 0	31-40 29 17 8 14 1 0 0 12 2 20 103 27 18.8 51-60 2 0 0 0 0 0 0 1 1 17 24 6.8 61-70 0 0 0 0 0 0 0 0 0 1.1 1 1.7 24 6.8 7.7 7.8 7.8 7.7											
51-60 2 0 1 <td>51-60 2 0 1<td></td><td></td><td>17 8</td><td>3 14</td><td></td><td></td><td></td><td></td><td></td></td>	51-60 2 0 1 <td></td> <td></td> <td>17 8</td> <td>3 14</td> <td></td> <td></td> <td></td> <td></td> <td></td>			17 8	3 14							
61 - 70 0<	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
71-80 0 <td>71-80 0<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td>	71-80 0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>											
% 21.1 12.3 0.0 1.3 1.0 1.7.3 1.0.0 FA-Fibroadenoma, FAis-Fibroadenomi, Kabs-Abscess, FCD-Fibrocy-tric disease, Gal-Galecocel, Latta-Lactational change, Granulo-Gr	% 42.1 12.3 6.0 13.4 0.5 1.0 1.0 1.7.3 100.0 FA-Fibroadenoma, FA/sEFibroadenoma, FA/S	71-80	0	0 () 0	0	0 0	0 0	1	1 0.3		
Table 1. Age Distribution of Ferma le Breast estation of the probability of the pro	Galactocele, Latta-Lattaional change, Granubo-Granubonatous lesion : Table 1. Age Distribution of Fernale Breast Lesions Total 1. 2ge Distribution of Fernale Breast Lesions Image Distribution of Fernale Breast Lesions Image Distribution of Fernale Breast Lesions Total 26.3 34 (8.9%) 18 (4.7%) 9 (2.4%) 18 (4.7%) UO-Upper outer, UI-Upper inter, LO-Lower outer, LI-Cover inter Total 2.5.3 8.9% 4.7% Vol 0.47% IPPE Male mathematication of the second s											
Quadrant Quadrant Right 152 (39.8%) 34 (8.9%) 18 (4.7%) 9 (2.4%) 213 55.8% Total 263 67 34 18 (4.7%) 9 (2.4%) 16 (4.2%) 16 (4.2%) 16 (4.2%) 10.9 44.2% Total 263 67 34 18 382 100 % Table 2. Laterality and Quadrant Table 2. Laterality and Quadrant Table 2. Laterality and Quadrant FA 74 0 73 0	Laterality U0 Ul Lo Li Total % Right 152 (33.8%) 34 (8.9%) 18 (4.7%) 9 (2.4%) 19 4.4.2% Left 111 (29.1%) 33(6.6%) 16 (4.2%) 9 (2.4%) 16 4.4.2% Yo 66.8% 17.5% 8.9% 4.7% 18 382 100 % UO-Upper outer, UI-Upper inner, LO-Lower outer, LI-Lower inner Table 2. Laterality and Quadrant 10 % 0											
i at call if i and	Later alityUOUILOLITotal%0Right152 (39.8%)33 (8.9%)16 (4.2%)9 (2.4%)16 344.2%Total26.3673418332100 %%66.8%17.5%8.9%4.7%18332100 %%66.8%17.5%8.9%4.7%18332100 %%66.8%17.5%8.9%4.7%18332100 %%66.8%7300000100%673492929292929292929292%74073000		Tab	ole 1. A	lge Di	stributio	on of Fema	le Breas	t Lesions			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				00/)	UI	LO					
Total 263 67 34 18 382 100 % % 68.8% 17.5% 8.9% 4.7% 100 % U-Upper outer, UI-Upper inner, UO-Lower outer, LI-Lower	Total 263 67 34 18 382 100 % % 668.8% 17.5% 8.9% 4.7% 77 UO-Upper outer, UI-Upper inner, LO-Lower outer, LI-Lower o											
U0-Upper outer, UI-Upper inner, LO-Lower outer, LI-Lower inner Table 2. Laterality and Quadrant HPE Malignant C Set of the set o	UD-Upper outer, UI-Uower outer, LI-Lower outer, LI-Lower outer, UI-Uower inner Table 2. Laterality and Quadrant Malignant C Note and the problem of the probl			263		67	34	18	382			
IPIE J. LUE VIEW UNDERVIEW IPIE INTERVIEW	Table 2. Laterality and Quartant IF able 2. Laterality and Quartant IF able 3. Laterality and Quartant		outo									
Part of the second sec	r Benign Malignant r FA 74 0 73 0 0 0 0 0 1 0 0 0 r FA 74 0 73 0	00-opper	oute									
FA 74 0 73 0 0 0 0 1 0 0 Abs. 5 5 0 <th0< th=""><th>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</th><th></th><th></th><th></th><th></th><th>Benign</th><th>НР</th><th>Έ</th><th>Malignar</th><th>ıt</th></th0<>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					Benign	НР	Έ	Malignar	ıt		
FA 74 0 73 0 0 0 0 1 0 0 Abs. 5 5 0 <th0< th=""><th>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</th><th>c .</th><th>JIag</th><th></th><th></th><th></th><th>0</th><th>s</th><th>a</th><th>v v</th></th0<>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	c .	JIag				0	s	a	v v		
FA 74 0 73 0 <td>$\begin{array}{c ccccccccccccccccccccccccccccccccccc$</td> <td>L i</td> <td>CAL</td> <td>otal</td> <td>Vbs</td> <td>FA asis</td> <td>and CD</td> <td>-NC</td> <td>ILC '-Fa</td> <td>D C C</td>	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	L i	CAL	otal	Vbs	FA asis	and CD	-NC	ILC '-Fa	D C C		
Abs. 5 5 0 <td>Abs. 5 5 0 <th0< th=""></th0<></td> <td></td> <td></td> <td>Ē</td> <td>4</td> <td>Ä</td> <td>F Gra</td> <td><u> </u></td> <td><u> </u></td> <td>ML</td>	Abs. 5 5 0 <th0< th=""></th0<>			Ē	4	Ä	F Gra	<u> </u>	<u> </u>	ML		
Abs. 5 5 0 <td>Abs. 5 5 0 <th0< th=""></th0<></td> <td>F</td> <td>A</td> <td>74</td> <td>0</td> <td>73 0</td> <td>0 0</td> <td>0 0</td> <td>) 1</td> <td>0 0</td>	Abs. 5 5 0 <th0< th=""></th0<>	F	A	74	0	73 0	0 0	0 0) 1	0 0		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Al	os.		5	0 0	0 0	0 0	0 0	0 0		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
% 3.2 4.8.2 1.3 1.6.7 0.6 2.7.6 0.6 <	% 3.2 48.2 1.3 16.7 0.6 27.6 0.6 <th0< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th0<>											
CytDiag-Cytologic Diagnosis, HPE-Histopathologic Examination, FA-Fibroadenoma, Abs-Abscess, Fasis-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulomatou mastitis, IDC-Infiltrating duct carcinoma, Med Ca-Medullary carcinoma, Muc Ca-Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Image: State of the second colspan="2">Image: State of the second colspan="2">Study Image: Study colspan="2">Study Image: Study colspan="2">Study Study colspan="2">Study Study Year of No. of Benign Study Year of No. of Benign No. of Malignant Study Year of No. of Benign No. of Malignant Study Year of No. of Benign No. of Malignant No. of Benign No. of Study Study Colspan="2" Study <th <="" colspan="2" th=""><th>CytDiag-Cytologic Diagnosis, HPE-Histopathologic Examination, FA-Fibroadenoma, Abs-Abscess, Fais-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulomatou mastitis, IDC-Infiltrating lobular carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Mucinous carcinoma. Mucinous carcinoma. Jo print of Cytology with Histopathology Reports Set to the print of the</th><th></th><th>1</th><th>150</th><th></th><th></th><th></th><th></th><th></th><th></th></th>	<th>CytDiag-Cytologic Diagnosis, HPE-Histopathologic Examination, FA-Fibroadenoma, Abs-Abscess, Fais-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulomatou mastitis, IDC-Infiltrating lobular carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Mucinous carcinoma. Mucinous carcinoma. Jo print of Cytology with Histopathology Reports Set to the print of the</th> <th></th> <th>1</th> <th>150</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>		CytDiag-Cytologic Diagnosis, HPE-Histopathologic Examination, FA-Fibroadenoma, Abs-Abscess, Fais-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulomatou mastitis, IDC-Infiltrating lobular carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Mucinous carcinoma. Mucinous carcinoma. Jo print of Cytology with Histopathology Reports Set to the print of the		1	150						
Abs-Abscess, Fasis-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulo-matou mastitis, IDC-Infiltrating duct carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca-Medullary carcinoma, Muc Ca-Medullary carcinoma, Muc Ca-Medullary carcinoma, Med Ca-Medullary carcinoma, Muc Ca-Medullary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary, ILC-Infiltrating lobular, Mediana,	Abscess, Fasis-Fibroadenosis, FCD-Fibrocystic disease, Granulo-Granulo-matuum attitis, IDC-Infiltrating duct carcinoma, NOS-Not otherwise specified, Pay-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Image: Second Carcinoma, NOS-Not otherwise specified, Pay-Payillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Image: Second Carcinoma, NOS-Not otherwise specified, Pay-Pay-Payillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports Image: Second Carcinoma, NOS-Not otherwise specified, Pay-Pay-Payillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Mathematical Second Carcinoma, Mos Second Carcinoma, Mos Second Carcinoma, Muc Ca Mucinous carcinoma, Mus Carcin		vtolo	gic Dia								
Mastitis, IDC-Infiltrating locular carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc	mastitis, IDC-Infiltrating lobular carcinoma, NOS-Not otherwise specified, Pap-Papillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports magnillary, ILC-Infiltrating lobular carcinoma, Med Ca-Medullary carcinoma, Muc Ca Mucinous carcinoma. maple 3. Comparison of Cytology with Histopathology Reports Magnitize and the second of t											
Mucinous carcinoma: Table 3. Comparison of Cytology with Histopathology Reports Appin Jo physy Jag group of the transform of transform of the transform of	Mucinous carcinoma. Table 3. Comparison of Cytology with Histopathology Reports n <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>											
Table 3. Comparison of Cytology with Histopathology Reports hp Jo. phys Jages 2005 hot of phys Jossof 2005 fight of phys fight of phys <th>Table 3. Comparison of Cytology with Histopathology Reports n jo npil aquiny o n<th></th><th></th><th></th><th>ing lobi</th><th>ılar carcir</th><th>ioma, Med C</th><th>a-Medulla</th><th>ry carcinor</th><th>na, Muc Ca-</th></th>	Table 3. Comparison of Cytology with Histopathology Reports n jo npil aquiny o n <th></th> <th></th> <th></th> <th>ing lobi</th> <th>ılar carcir</th> <th>ioma, Med C</th> <th>a-Medulla</th> <th>ry carcinor</th> <th>na, Muc Ca-</th>				ing lobi	ılar carcir	ioma, Med C	a-Medulla	ry carcinor	na, Muc Ca-		
h h	N N				ricon	of Cytol	oav with F	listonath	ology Ra	norts		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	n jo n i	Tubi	0.01	Jompt	113011	oj cytor		iistoputii	ology ne	ports		
Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Com	Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁶ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4					ory	nign	_	IS	¥		
Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Com	Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁶ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4	ły	,	ly of	ber	act	3en	%) [ca]	iot	%) Nar		
Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Com	Ukah and Oluwasola ¹² 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.6) 447 (31.9) Challa et al ¹³³ 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et al ² 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 65 (28.9) Chokshi and Mehta ¹⁴⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁶ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4	trič		tuc	C II	l (°	Ē	ž	bic	je ji		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Oluwasolati 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.5) 447 (31.9) Challa et ali 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et ali 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 6 (5 (28.9) Chokshi and Mehta ¹⁴¹ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani1 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of th	S	;	z s	of	sat C	2	A C	C, C	Ma] C		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Oluwasolati 2005 1401 38 (2.7) 803 (57.3) 6 (0.4) 107 (7.5) 447 (31.9) Challa et ali 2010 812 8 (0.9) 314 (38.6) 27 (3.3) 12 (1.4) 451 (55.5) Sankaye et ali 2012 225 13 (5.8) 131 (58.2) 8 (3.6) 8 (3.5) 6 (5 (28.9) Chokshi and Mehta ¹⁴¹ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani1 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of th					Un	C2		S	-		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			2005	1401	20 (2 7)			107 (7.6)	447 (31.9)		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $		1 ¹²	2005	1401	30 (2.7)	803 (57.3)	6 (0.4)	107 (7.0)			
Mehta ¹⁴ 2012 407 28 (5.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁶ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Cases (%) Cases (%) Cases (%) Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012	Mehta ¹⁴ 2012 407 28 (6.9) 293 (71.9) 8 (2) 8 (2) 70 (17.2) Singh et al ¹⁵ 2014 100 5 (5) 51 (51) 2 (2) 3 (3) 39 (39) Arul and Masilamani ¹¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Cases (%) Cases (%) Cases (%) Cases (%) Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 3	ununu ce u	112		812		314 (38.6)	27 (3.3)				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sankaye et	112 113 2 al2 2	2010	812	8 (0.9)	314 (38.6)	27 (3.3)	12 (1.4)			
Arul and Masilamani ¹ 2015 523 14 (2.7) 352 (67.3) 27 (5.2) 41 (7.8) 89 (17) Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁶ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Cases (%) Cases (%) Tota Study Year of Study No. of Benign Cases (%) No. of Malignant Cases (%) Tota Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 117 (58.5) 83 (41.5) 200 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sankaye et Chokshi a	1 ¹² ¹³ 2 ¹³ 2 ¹³ 2 ¹³ 2 ¹² 2 ¹² 2 ¹² 2 ¹² 2	2010 2012	812 225	8 (0.9) 13 (5.8)	314 (38.6) 131 (58.2)	27 (3.3) 8 (3.6)	12 (1.4) 8 (3.5)	451 (55.5) 65 (28.9)		
Mashamani ¹ Mashamani ¹ Madubogwu et al ¹⁰ 2017 110 17 46 5 4 38 Veena et al ¹⁰ 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Year of No. of Benign No. of Malignant Study Cases (%) Cases (%) Tota Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Mashmania Year of No. of Benign No. of Malignant Cancer Institute Guidelines Comparison of the Distribution of Various National Cancer Table 4. Comparison of the Distribution of Various National Cancer Study Year of No. of Benign No. of Malignant Cases (%) Cases (%) Total Cases (%) Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹³⁷ 2006 102 (56) 80 (44) 182 Sudy and Dongre ² 2012 312 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2017 58 (52.7) 52 (47.3) 110 Vene at al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴	113 al ² al ²	2010 2012 2012	812 225 407	8 (0.9) 13 (5.8) 28 (6.9)	314 (38.6) 131 (58.2) 293 (71.9)	27 (3.3) 8 (3.6) 8 (2)	12 (1.4) 8 (3.5) 8 (2)	451 (55.5) 65 (28.9) 70 (17.2)		
et al 10 2017 110 17 46 5 4 38 Veena et al 16 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Year of No. of Benign No. of Malignant Total (1.4) Study Cases (%) Cases (%) Cases (%) Total (1.4) 182 Vehansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	et al 10 2017 110 17 46 5 4 38 Veena et al 16 2017 178 4 (2.2) 134 (75.28) 14 (7.8) 6 (3.3) 20 (11.2) Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Year of Study No. of Benign Cases (%) No. of Malignant Cases (%) Total Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁰ 2017 112 (78.9) 30 (21.1)	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and	112 113 12 12 13 12 12 12	2010 2012 2012 2012 2014	812 225 407 100	8 (0.9) 13 (5.8) 28 (6.9) 5 (5)	314 (38.6) 131 (58.2) 293 (71.9) 51 (51)	27 (3.3) 8 (3.6) 8 (2) 2 (2)	12 (1.4) 8 (3.5) 8 (2) 3 (3)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39)		
Versent study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studies No. of Malignant Tota Study Year of Study No. of Benign No. of Malignant Tota Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Present study 2019 382 0 290 (75.8) 22 (5.8) 4 (1.0) 66 (17.3) Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studies Study Year of Study No. of Benign Cases (%) No. of Malignant Total Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹³⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Masilama	$ ^{12}$ $ ^{13}$ $ ^{13}$ $ ^{13}$ $ ^{15}$ $ ^{15}$ $ ^{15}$ $ ^{15}$ $ ^{11}$	2010 2012 2012 2012 2014 2015	812 225 407 100 523	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7)	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2)	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17)		
Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Year of No. of Benign No. of Malignant Tota Study Cases (%) Cases (%) Cases (%) Tota Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Table 4. Comparison of the Distribution of Various National Cancer Institute Guidelines Comparison of Present Study with Published Studie Study Year of Study No. of Benign Cases (%) No. of Malignant Cases (%) Total Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Cases (%) 206 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Daramola et al ⁶ 2017 15 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a: Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰	a ¹² al ² al ² nd a ¹⁵ a ¹⁵ a ¹⁵ a ¹⁵ a ¹⁵ a ¹ a ¹⁵	2010 2012 2012 2014 2015 2017	812 225 407 100 523 110	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38		
Study Year of Study No. of Benign Cases (%) No. of Malignant Cases (%) Tota Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Year of Study No. of Benign Cases (%) No. of Malignant Cases (%) Total Total Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 158 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a: Mehta ¹⁴ Singh et a Arul and Masilamai Madubogy et al ¹⁰ Veena et a	a ¹² al ² nd l ¹⁵ i ni ¹ wu	2010 2012 2012 2014 2015 2017 2017	812 225 407 100 523 110 178	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2)	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5) 14 (7.8)	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2)		
Study Study Cases (%) Cases (%) 10tz Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Study Study Cases (%) Cases (%) 104 Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2017 58 (52.7) 52 (47.3) 110 Veen at al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰ Veena et a Present stu	a ¹² al ² al ² al ² al ¹⁵ al ¹⁵ al ¹⁶ al ¹⁶	2010 2012 2012 2014 2015 2017 2017 2017	812 225 407 100 523 110 178 382	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5) 14 (7.8) 22 (5.8)	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3)		
Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Ukah and Oluwasola ¹² 2005 126 (50.4) 124 (49.6) 250 Nguansangiam et al ¹⁷ 2006 102 (56) 80 (44) 182 Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰ Veena et a Present stu Table	112 [1]13 [1]13 [1]15 [1]15 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]17 [2010 2012 2012 2014 2015 2017 2017 2019 mpari elines	812 225 407 100 523 110 178 382 ison of Comp	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 <i>the Dist</i> <i>arison o</i>	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5) 14 (7.8) 22 (5.8) f Various Study with	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studies		
Sankaye and Dongre ² 2012 31 (40.6) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Sankaye and Dongre ² 2012 31 (40.8) 45 (59.2) 76 Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a: Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰ Veena et a Present stu Table	112 113 113 115 115 115 115 115 115	2010 2012 2012 2014 2015 2017 2017 2019 mpari elines	812 225 407 100 523 110 178 382 Son of Comp	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 <i>The Dist</i> <i>arison o</i>	314 (36.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5) 14 (7.8) 22 (5.8) 5 <i>Various</i> 5 <i>Various</i> 5 1 No. 6	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National Publish	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie:		
Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Yusuf and Atanda ¹⁸ 2012 117 (58.5) 83 (41.5) 200 Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul anc Masilamaa Madubogy et al ¹⁰ Veena et a Present stu Table Institute	112 113 113 115 115 115 116 116 116 116 116	2010 2012 2012 2014 2015 2017 2017 2019 mpari elines	812 225 407 100 523 110 178 382 son of Comp Year of Study 2005	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 the Dist arison o y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S of Benigr ases (%) 26 (50.4)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (% 124 (49.6)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studied tant Tota 250		
Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286	Arul and Masilamani ¹ 2015 198 (69.2) 88 (30.8) 286 Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul anc Madubogy et al ¹⁰ Veena et a Present str Table Institute	112 113 113 115 115 115 115 116 116 116 116	2010 2012 2012 2014 2015 2017 2017 2019 mpari elines sola ¹² et al ¹⁷	812 225 407 100 523 110 178 382 Son of Comp Year of Stud 2005 2006	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 the Dist arison of y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution of f Present S of Benigr asses (%) 26 (50.4) 102 (56)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (%) 124 (49.6) 80 (44)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) <u>66 (17.3)</u> Cancer ed Studie mant Tota 250 182		
	Daramola et al ⁶ 2015 398 (91.3) 38 (8.7) 436 Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰ Veena et a Present str Table Institute Stu Ukah and G Nguansan; Sankaye a	112 2 113 21 al2 2 al2 2 al2 2 al1 2 al2 3 al2 3 <td>2010 2012 2012 2014 2015 2017 2017 2017 2019 mpari elines sola¹² et al¹⁷ ngre²</td> <td>812 225 407 100 523 110 178 382 son of Comp Year of Study 2005 2006 2012</td> <td>8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 <i>The Dist</i> <i>arison o</i> of No y C</td> <td>314 (36.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution op f Present S of Benign ases (%) .26 (50.4) 102 (56) 31 (40.8)</td> <td>27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various</td> <td>12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2)</td> <td>451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie mant Tota 250 182 76</td>	2010 2012 2012 2014 2015 2017 2017 2017 2019 mpari elines sola ¹² et al ¹⁷ ngre ²	812 225 407 100 523 110 178 382 son of Comp Year of Study 2005 2006 2012	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 <i>The Dist</i> <i>arison o</i> of No y C	314 (36.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution op f Present S of Benign ases (%) .26 (50.4) 102 (56) 31 (40.8)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie mant Tota 250 182 76		
Daramola et al ^o 2015 398 (91.3) 38 (8.7) 436	Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present stu Table Institute Stu Ukah and (Nguansan Sankaye a Yusuf and	112 21 113 21 al2 21 al2 21 al1 21 1	2010 2012 2012 2014 2015 2017 2017 2017 2019 mpari elines usola ¹² et al ¹⁷ ngre ² uda ¹⁸	812 225 407 100 523 110 178 382 son of Comp Year of Study 2005 2006 2012 2012	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 7 the Dist arison o 0 0 f No y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution o f Present S of Benigr ases (%) .26 (50.4) 102 (56) 31 (40.8) .17 (58.5)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer 250 182 76 6 200		
	Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str. Table Institute Ukah and (Nguansan, Sankaye ai Yusuf and Arul and M	112 113 12 113 21 12 115 1 115 115 1 116 115 1 116 116 1 116 119 1 116 110 1 116 111 <	2010 2012 2012 2014 2015 2017 2017 2019 mpari elines sola ¹² et al ¹⁷ ngre ² ngre ²	812 225 407 100 523 110 178 382 son of Comp Year of Study 2005 2006 2012 2012 2012	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 the Dist arison o y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution of fPresent S of Benigt ases (%) 26 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr (ases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) <u>66 (17.3)</u> Cancer ed Studied 182 76 200 182 76 200 286		
Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110	* * * * *	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present stu Table Institute Ukah and (Nguansan, Sankaye a Yusuf and Arul and M	112 al2 al2 al2 al2 al2 al2 al2 al2 al1 al2 al2 lp5 al2 al2 lp6 al2 al2 lp16 al2 al2 aldy al2 al2 al2 al2 al2 al2 al2 al2 al2 al2 al2 al3 al2 al2 al4 al2 <	2010 2012 2012 2014 2015 2017 2017 2017 2017 2019 mpari elines sola ¹² et al ¹⁷ ngre ² dd ¹⁸ mani ¹ al ⁶	812 225 407 100 523 110 178 382 cson of Comp Year c Study 2005 2012 2012 2015 2015	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 the Dist arison of v C 1 1 1 1 1 1 1 1 1 1 1 1 1	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution of f Present S of Benigra asse (%) 126 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2) 398 (91.3)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (% 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8) 38 (8.7)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) <u>66 (17.3)</u> Cancer ed Studied Tota 250 182 76 200 2866 436		
Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142	Table 5. Comparison of Histopathological Cases	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str Table Institute Str Ukah and Q Nguansan Sankaye a Yusuf and Arul and M Daramo Madubog Veena	112 112 113 21 114 112 115 11 115 11 115 11 116 21 118 24 Cond Guidd Iddy 24 Iddy 24<	2010 2012 2014 2015 2017 2017 2017 2017 2017 2017 2017 2017	812 225 407 100 523 110 178 382 son of Comp Year (Study 2005 2012 2012 2012 2015 2017 2017	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 5 (the Dist arison of No y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S of Benigr ases (%) 26 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2) 398 (69.2) 398 (91.3) 58 (52.7) 12 (78.9)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8) 38 (8.7) 52 (47.3) 30 (21.1)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer 250 182 76 200 286 436 1100 142		
Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142 Present study 2019 109 (70) 47 (30) 156		Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str Table Institute Str Ukah and Q Nguansan Sankaye a Yusuf and Arul and M Daramo Madubog Veena	113 :: 113 :: 113 :: nd :: 115 :: 115 :: 116 :: 117 :: 118 :: 119 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 :: 110 : 110 : 110 : 110 : 110 : 110 : 110 : 110 <td:< td=""> 110</td:<>	2010 2012 2012 2014 2015 2017 2017 2017 2017 2017 2017 2017 2017	812 225 407 100 523 110 178 382 son of Comp Year (Study 2005 2016 2012 2015 2017 2017 2017	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 5 (the Dist arison o 5 (No y C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution o f Present S of Benigu ases (%) 26 (50.4) 102 (56) 31 (40.8) 31 (40.8) 117 (58.5) 98 (69.2) 98 (69.2) 98 (69.2) 98 (69.2) 12 (78.9) 109 (70)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 14 (7.8) 22 (5.8) 7 Various 5 7 Various 1 No. 4	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish of Maligr Cases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (3.8) 38 (8.7) 52 (47.3) 30 (21.1) 47 (30)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer ed Studie Tota 250 182 76 200 286 4363 110		
Daramola et al ^o 2015 $398(91.3)$ $38(8.7)$ 43	Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 11 Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 14 Present study 2019 109 (70) 47 (30) 15	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Masilaman Madubogy et al ¹⁰ Veena et a Present stu Table	112 [1]13 [1]13 [1]15 [1]15 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]16 [1]17 [2010 2012 2012 2014 2015 2017 2017 2019 mpari	812 225 407 100 523 110 178 382 son of	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 <i>(the Dist.</i>	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5) 14 (7.8) 22 (5.8) f Various	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National	451 (55.) 65 (28.9 70 (17.2 39 (39) 89 (17) 38 20 (11.2 66 (17.3 Cancer		
Madubogwu et al ¹⁰ 2017 58 (52.7) 52 (47.3) 110	Present study 2019 109 (70) 47 (30) 156	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present stu Table Institute Ukah and (Nguansan, Sankaye a Yusuf and Arul and M	112 al2 al2 al2 al2 al2 al2 al2 al2 al1 al2 al2 lp5 al2 al2 lp6 al2 al2 lp16 al2 al2 aldy al2 al2 al2 al2 al2 al2 al2 al2 al2 al2 al2 al3 al2 al2 al4 al2 <	2010 2012 2012 2014 2015 2017 2017 2017 2017 2019 mpari elines sola ¹² et al ¹⁷ ngre ² dd ¹⁸ mani ¹ al ⁶	812 225 407 100 523 110 178 382 cson of Comp Year c Study 2005 2012 2012 2015 2015	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 the Dist arison of v C 1 1 1 1 1 1 1 1 1 1 1 1 1	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution of f Present S of Benigra asse (%) 126 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2) 398 (91.3)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (1.4) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National h Publish of Maligr cases (% 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8) 38 (8.7)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) <u>66 (17.3)</u> Cancer ed Studied Tota 250 182 76 200 2866 4366		
Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142	Table 5. Comparison of Histopathological Cases	Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str Table Institute Str Ukah and Q Nguansan Sankaye a Yusuf and Arul and M Daramo Madubog Veena	112 112 113 21 114 112 115 11 115 11 115 11 116 21 118 24 Cond Guidd Iddy 24 Iddy 24<	2010 2012 2014 2015 2017 2017 2017 2017 2017 2017 2017 2017	812 225 407 100 523 110 178 382 son of Comp Year (Study 2005 2012 2012 2012 2015 2017 2017	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 5 (the Dist arison of No y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S of Benigr ases (%) 26 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2) 398 (69.2) 398 (91.3) 58 (52.7) 12 (78.9)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8) 38 (8.7) 52 (47.3) 30 (21.1)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer 250 182 76 200 286 436 1100 142		
Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142		Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str Table Institute Str Ukah and Q Nguansan Sankaye a Yusuf and Arul and M Daramo Madubog Veena	112 112 113 21 114 112 115 11 115 11 116 12 118 14 119 14 110 14 111 14 <	2010 2012 2014 2015 2017 2017 2017 2017 2017 2017 2017 2017	812 225 407 100 523 110 178 382 son of Comp Year (Study 2005 2012 2012 2012 2015 2017 2017	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 5 (the Dist arison of No y C	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution oj f Present S of Benigr ases (%) 26 (50.4) 102 (56) 31 (40.8) 17 (58.5) 98 (69.2) 398 (69.2) 398 (91.3) 58 (52.7) 12 (78.9)	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 1 14 (7.8) 22 (5.8) f Various ft Various ft Various ft Various ft Various	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish of Maligr cases (%) 124 (49.6) 80 (44) 45 (59.2) 83 (41.5) 88 (30.8) 38 (8.7) 52 (47.3) 30 (21.1)	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer 250 182 76 200 286 436 1100 142		
Veena et al ¹⁶ 2017 112 (78.9) 30 (21.1) 142		Sankaye et Chokshi a Mehta ¹⁴ Singh et a Arul and Madubogy et al ¹⁰ Veena et a Present str Table Institute Str Ukah and Q Nguansan Sankaye a Yusuf and Arul and M Daramo Madubog Veena	113 113 113 113 nd 12 114 114 115 1 116 1 117 1 118 1 119 1 119 1 110 1	2010 2012 2014 2015 2017 2017 2017 2017 2017 2017 2017 2017	812 225 407 100 523 110 178 382 son of Comp Year (Study 2005 2006 2012 2012 2012 2012 2012 2017 2017 2017	8 (0.9) 13 (5.8) 28 (6.9) 5 (5) 14 (2.7) 17 4 (2.2) 0 7 7 4 (2.2) 0 7 7 4 (2.2) 0 7 7 4 (2.2) 0 7 7 4 (2.2) 0 7 7 4 (2.7) 17 4 (2.7) 17 4 (2.7) 17 4 (2.7) 17 4 (2.7) 0 7 7 7 4 (2.7) 17 4 (2.7) 17 17 4 (2.7) 17 4 (2.7) 17 17 17 17 17 17 17 17 17 17	314 (38.6) 131 (58.2) 293 (71.9) 51 (51) 352 (67.3) 46 134 (75.28 290 (75.8) ribution o f Present S cof Benigu ases (%) 26 (50.4) 102 (56) 31 (40.8) 31 (40.8) 117 (58.5) 98 (69.2) 98 (91.3) 58 (52.7) 12 (78.9) 109 (70) of Histopa	27 (3.3) 8 (3.6) 8 (2) 2 (2) 27 (5.2) 5 14 (7.8) 22 (5.8) 7 Various 5 5 Various 1 No. (C	12 (14) 8 (3.5) 8 (2) 3 (3) 41 (7.8) 4 6 (3.3) 4 (1.0) National b Publish 5 (41,0) 80 (44) 45 (59.2) 83 (41.5) 88 (3.41.5) 88 (3.41.5) 88 (3.41.5) 88 (3.41.5) 88 (3.41.5) 88 (3.41.5) 83 (42.7) 83 (42.7) 84 (42.7) 84 (42.7) 84 (42.7) 84 (42.7) 84	451 (55.5) 65 (28.9) 70 (17.2) 39 (39) 89 (17) 38 20 (11.2) 66 (17.3) Cancer ed Studie Cancer 250 182 76 200 286 436 1100 142		

Study	Year of Study	Sensitivity % (95% Cl)	Specificity % (95% Cl)	PPV % (95% CI)	NPV % (95% CI)	Accuracy %						
Sankaye and Dongre ²	2012	88.37	96.42	97.43	84.37	91.54						
Arul and Masilamani ¹	2015	93.1 (88.2%- 95%)	99 (96.8%- 99.8%)	97.6 (92.5%- 99.6%)	97 (94.9%- 97.8%)	97.20						
Madubogwu et al ¹⁰ Veena et al ¹⁶												
Present Study	2019	93.62 (82.46%– 98.66%)	100 (96.67%- 100%)	100 (92.5%- 99.6%)	97.32 (92.4%- 99.09%)	98.08						
	-	arison of St ent Study w										

DISCUSSION

In the present study, benign breast lesions were more common in 21–30 years, which was similar to studies by Veena et al.¹⁶ Malignant breast lesions were most common in 41–50 years, which were comparable to studies by Arul et al.¹ The present study shows that benign lesions are common in the younger age group and malignancy rates increase with increasing age of patients. The right breast (213, 55.8%) was found to be more commonly involved in the present study, which was in contrast to some published findings^{1,2}; however, the upper outer quadrant (263, 68.8%) was the most common location which is similar to findings by the same researchers.^{1,2}

The distribution of the FNAC diagnoses of breast lesions using NCI guidelines (1996) in our institution as compared with published studies is shown in Table 4. Categories C2 to C5 of our study were comparable to frequencies found in most published studies. In the present study, there were no C1 categories, since rapid stain was conducted for all cases to determine specimen adequacy; Categories C2 and C5 are straightforward and has been associated with a high degree of diagnostic accuracy as was observed in the present study (99% and 100% respectively). However, the interpretation of C3 and C4 are difficult and confusing because they do not have strict criteria for diagnosis. Some researchers have suggested clubbing ofC3 and C4 as a single term called equivocal/suspicious category as they believe that a Core needle biopsy (CNB) or surgical biopsy should be done for this combined category, as the incidence of malignancy is significant in both subgroups. In the present study, benign and malignant outcome of C3 was 71.4% and 28.6%, while malignant outcome of C4 was 100%, which is comparable to large-scale studies with histopathological correlation. Since the current study showed 71.4% benign lesions with C3 and 100% malignancy with C4, we feel that it is still useful to maintain the categories C3 and C4 separately.

On HPE of the 156 cases, benign cases (69.9%, 109/156) were more common as compared to malignant cases (30.1%, 47/156). This finding was similar to various studies^{1,16,18,17} [Table 4].The most common benign and malignant breast lesions on HPE was fibroadenoma and IDC-NOS respectively. These findings were comparable to various published studies.^{1,2,7,8,10,16,18} One case of ILC was under-diagnosed as fibroadenoma in C2, one case of IDC-NOS and papillary misdiagnosed as C3 on FNAC, contributing to false negative

Original Research Article

results. Factors contributing to false negative results may include the small size of the lesion, hypocellularity, and inadequate sampling during aspiration, histological tumour types such as low nuclear grade in ILC, and well-differentiated intracystic papillary carcinoma. All cases from C4 and C5 was diagnosed as malignant on HPE. These results were considered as true positive. Both false negative and false positive diagnoses can be reduced by good sampling technique, proper tumour localization, triple assessment, and more importantly availing expert second opinions for doubtful cases.

The present study showed a sensitivity of 93.62% (95% CI, 82.46%-98.66%), specificity of 100% (95% CI, 96.67%-100%), PPV of 100% (95% CI, 92.5%-99.6%), NPV of 97.32% (95% CI, 92.4%-99.09%), and accuracy of 98.08% for FNAC in the diagnosis of malignant lesions, comparable to other published studies as in Table 6.

CONCLUSIONS

Fine-needle aspiration cytology is a rapid and effective method for the primary categorization of palpable breast lumps into benign, malignant, atypical, suspicious, and unsatisfactory categories. Benign breast lesions are common than malignant lesions, fibroadenoma is the most common benign breast lesion, whereas IDC accounts for the highest number of malignant lesions. Histological correlation indicated FNAC to be a good diagnostic tool.

REFERENCES

- Arul P, Masilamani S. Application of National Cancer Institute recommended terminology in breast cytology. J Can Res Ther 2017;13(1):91-6.
- [2] Sankaye SB, Dongre SD. Cytological study of palpable breast lumps presenting in an Indian rural setup. Indian J Med Paediatr Oncol 2014;35(2):159-64.
- [3] Chaudhury SMSA, Alam MK, Haque MS. The role of FNAC in diagnosis of breast disease at different ages - 208 cases. Journal of Bangladesh College of Physicians and Surgeons 2012;30(3):137-40.
- [4] Pandya AN, Shah NP. Breast fine needle aspiration cytology reporting: a study of application of probabilistic approach. Indian Medical Gazette 2013: p. 54-9.
- [5] Orell SR, Sterrett GF, Whitaker D, et al. Breast. Fine needle aspiration cytology. 4th edn. Churchill Livingstone 2005: p. 165-217.
- [6] Daramola AO, Odubanjo MO, Obiajulu FJ, et al. Correlation between fine-needle aspiration cytology and histology for palpable breast masses in a Nigerian Tertiary Health Institution. International Journal of Breast Cancer 2015;2015:742573.
- [7] Rupom TU, Choudhury T, Banu SG. Study of fine needle aspiration cytology of breast lump: correlation of cytologically malignant cases with their histological findings. BSMMU J 2011;4(2):60-4.
- [8] Almobarak AO, Elhassan TM, Elhoweris MH, et al. Cytomorphologic patterns of breast lesions in Sudanese

patients: lessons learned from fine needle aspiration cytology. Asian Pac J Cancer Prev 2014;15(8):3411-3.

- [9] Kumar CA, Kumar PA, Tarannum K, et al. Study of breast lesions in a tertiary care centre: a retrospective study. Med Phoenix: An Official Journal of NMC, Birgunj, Nepal 2017;2(1):48-51.
- [10] Madubogwu CI, Ukah CO, Anyanwu Snc, et al. Subclassification of breast masses by fine needle aspiration cytology. Eur J Breast Health 2017;13(4):194-9.
- [11] Tiwari M. Role of fine needle aspiration cytology in diagnosis of breast lumps. Kathmandu University Medical Journal 2007;5(2):215-7.
- [12] Ukah CO, Oluwasola OA. The clinical effectiveness of fine needle aspiration biopsy in patients with palpable breast lesions seen at the University College Hospital, Ibadan, Nigeria: a 10-year retrospective study. J Cytol 2011;28(3):111-3.
- [13] Challa VR, Guru BGY, Rangappa P, et al. Cytological and pathological correlation of FNAC in assessing breast lumps and axillary lymph node swellings in a public

sector hospital in India. Patholog Res Int 2013;2013:695024.

- [14] Chokshi MH, Mehta NP. Cytological study of palpable breast lumps (407 cases) with their histological correlation. Int J Med Sci Public Health 2014;3(2):181-5.
- [15] Singh P, Chaudhry M, Nauhria S, et al. Cytomorphological patterns of breast lesions diagnosed on fine-needle aspiration cytology in a tertiary care hospital. Int J Med Sci Public Health 2015;4(5):674-9.
- [16] Veena KL, Vani R, Jijiya BP, et al. Evaluation of breast lumps by fine needle aspiration cytology in correlation with histopathology. J Cont Med A Dent 2017;5(1):63-7.
- [17] Nguansangiam S, Jesdapatarakul S, Tangjitgamol S. Accuracy of fine needle aspiration cytology from breast masses in Thailand. Asian Pac J Cancer Prev 2009;10(4):623-6.
- [18] Yusuf I, Atanda AT. Validity of fine needle aspiration cytology of the palpable breast lesions: a teaching hospital experience. Niger J Basic Clin Sci 2014;11(1):36-40.